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GROWING EVIDENCE FOR PSYCHODYNAMIC
THERAPY FOR DEPRESSION
Abstract. Psychodynamic therapy (PT) for depression is the least examined treat-
ment method for depression, compared to cognitive-behavioral therapy (CBT)
and interpersonal therapy. This article, consisting of five randomized clinical tri-
als of short psychodynamic supportive psychotherapy (SPSP) conducted over
the last 25 years in Amsterdam, will review the trial results to provide answers to
the question about which role SPSP can play in the treatment of depression. The
researchers conclude that it is justified to qualify SPSP an empirically supported
therapy form of PT for depression. In particular, adding SPSP to pharmacother-
apy yields better results than pharmacotherapy by itself. Adding medication to
SPSP may have a significant added value, but it is not as large as in the first
comparison. The results also confirm no difference in efficacy between CBT and
SPSP.
Keywords: depression, short psychodynamic supportive psychotherapy, clinical
trial, evidence-based practice, psychodynamics, clinical effectiveness
Introduction
Depression is one of the most prevalent mental disorders worldwide.
The lifetime prevalence ranges from 15% to 20% (Kessler et al., 1994).
Depression is currently treated in different ways. It is well established
Address correspondence to Jack J. M. Dekker, Ph.D., Arkin Institute for Mental Health,
Klaprozenweg 111, Amsterdam, 1033 NN, Netherlands. E-mail: jack.dekker@arkin.nl
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132 JACK J. M. DEKKER, Ph.D. ET AL.
that psychological interventions are effective in the treatment of depres-
sion. In recent decades, a large number of trials have been conducted in
which the effects of psychological treatments of depression have been
examined. These studies clearly show that psychological treatments have
large effects in terms of symptom reductions and increased well-being
(Cuijpers, van Straten, Warmerdam, & Andersson, 2008). The most ex-
amined psychological treatment for depression is probably cognitive-
behavioral therapy (CBT), with interpersonal therapy coming next. Short-
term psychodynamic therapy (PT) is probably the least examined treat-
ment method of these three therapies.
The efficacy of PT for depression was the focus of three meta-analyses.
The first meta-analysis (Leichsenring, 2001) included six studies compar-
ing PT with CBT and found that both psychotherapies were equally effec-
tive in the treatment of depression, a result the author suggested should
be regarded as preliminary, due to the small number of included studies.
The second meta-analysis (Churchill et al., 2001) compared PT to CBT
and found that patients receiving CBT were more likely to recover than
those receiving PT, but found no differences in posttreatment symptoms,
symptom reduction, or drop-out. The third meta-analysis of our own re-
search group (Driessen et al., 2007) was the most extensive study, and
included many more trials than the first two meta-analyses. This study
included 23 studies encompassing a total of 1,365 subjects (713 in the PT
conditions, 551 in the alternative psychotherapy conditions, and 101 in
the control conditions). In this last meta-analysis, PT appeared effective
in the treatment of depression in adults. The pre- to posttreatment effects
were consistently large, indicating a significant reduction of depressive
symptoms after PT. These reductions were maintained at three-month,
six-month, and one-year follow-ups. In this analysis no significant dif-
ferences between PT and other psychotherapies were apparent at the
three-month follow-up, but a nonsignificant trend did indicate a possible
small superiority of the other psychotherapies at the one-year follow-
up. The authors of the last meta-analysis concluded that PT resulted in
a large and enduring decrease of depression levels, that PT was more
effective than control conditions, and that PT may be considered to be
an empirically validated treatment method for depression.
In the 1970s and 1980s, different types of short-term PT (all based on
psychoanalytic models) were developed by Malan (1963), Mann (1973),
Sifneos (1979), Davanloo (1980), Luborsky (1984), Strupp and Binder
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EVIDENCE FOR PSYCHODYNAMIC THERAPY 133
(1984), and Pollack and Horner (1985). The most recently developed and
extensively studied variant in the family of psychodynamic treatments is
the Short Psychodynamic Supportive Psychotherapy (SPSP), developed
in the early 1990s as a structured treatment for depressed outpatients by
De Jonghe (De Jonghe, Rijnierse, & Janssen, 1994; De Jonghe et al., 2013).
SPSP is a face-to-face, individual psychotherapy, consisting of 16 sessions
in six months (eight weekly sessions, then eight fortnightly sessions). The
emphasis is on supportive techniques that counter regression and foster
psychological growth. The primary goal of SPSP is to cure depression.
The secondary goal is to reduce patients’ vulnerability to depression. For
a full description of the theory and methods of SPSP we refer to the most
recent article by De Jonghe et al. (2013).
Up to now, the efficacy of SPSP has been examined by a single re-
search group, who conducted five randomized clinical trials in similar but
different study populations, and used identical research designs (e.g., the
same instruments and assessment periods), with a research period of
each trial lasting about four years. In this article, we will review the trial
results of the last 25 years.
Methods
Goals of the Five RCTs
At the start of our study project we were interested in the incremental
value of SPSP in combination with pharmacotherapy. The second trial in-
vestigated the comparative efficacy of two versions of combined therapy,
one with eight sessions of SPSP and one with 16 sessions of SPSP. The
third trial assessed the relative efficacy of combined therapy and SPSP
on its own. The fourth trial concerned SPSP alone and pharmacotherapy
alone. And in the last trial SPSP is compared with an already empirically
supported therapy, namely CBT. In Table 1 the comparisons of all the
trials are listed.
The fourth trial started with a randomized clinical trial of eight weeks,
making a direct comparison between antidepressants and SPSP. At eight
weeks, all patients with less than a 30% decrease in symptoms were
offered combined therapy for an additional period of 16 weeks. Non-
responsive patients receiving antidepressants were therefore offered
complementary psychodynamic supportive psychotherapy, whereas
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Table 1
Comparisons of the Trials
Experimental
Arm Control Arm
First trial SPSP 16 sessions with
pharmacotherapy
versus Pharmacotherapy
Second trial SPSP 16 sessions with
pharmacotherapy
versus SPSP 8 sessions with
pharmacotherapy
Third trial SPSP 16 sessions with
pharmacotherapy
versus SPSP 16 sessions
Fourth trial SPSP 16 sessions versus Pharmacotherapy
Fifth trial SPSP 16 sessions versus CBT 16 sessions
SPSP = Short Psychodynamic Supportive Psychotherapy; CBT = Cognitive Behavioral
Therapy
nonresponsive patients receiving psychodynamic supportive psychother-
apy were offered complementary antidepressants. In the fifth trial, pa-
tients received antidepressants in addition to their psychotherapy if they
showed severe depressive symptoms (Hamilton Depression Rating Scale
score > 24) at the start of treatment.
The first trial started in June 1993 and had an inclusion period until
June 1995. The second trial started in August 1995 and had an inclusion
period of three years until September 1998. The third trial ran from April
1997 until June 2002. The fourth trial started in July 2002 and ran un-
til November 2005. The fifth trial started in February 2006 and had an
inclusion period until November 2009. The trials were all conducted in
various outpatient clinics in Amsterdam.
Study Samples
Inclusion. The samples of the five random controlled trials consisted
of new, consecutively registered depressed patients at three outpatient
clinics of the Mental Health Institution Arkin in Amsterdam. Patients were
referred by general practitioners. In addition to written consent, inclusion
criteria were: age between 18 and 65 years and a DSM-III-R (American
Psychiatric Association [APA], 1980) or DSM-IV (APA, 1994) defined Major
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EVIDENCE FOR PSYCHODYNAMIC THERAPY 135
Table 2
Hamilton Depression Rating Scale (HAM-D) Inclusion Criteria and Mean
Baseline HAM-D Scores at Baseline of All the Trials
Severity of Depression
HAM-D Inclusion
Criterion at Baseline
First trial Mild, moderate and severe > = 14
Second trial Mild, moderate and severe > = 14
Third trial Mild and moderate > 11 and <25
Fourth trial Mild and moderate > 11 and <27
Fifth trial Mild, moderate and severe > = 14
Depression with or without dysthymia. The DSM diagnosis was assessed
by means of a semi-structured interview (Huyser, De Jonghe, Sno, &
Schalken, 1996). A further inclusion criterion was a certain score on the
17-item Hamilton Depression Rating Scale (HAM-D; Hamilton, 1967). In
Table 2, the HAM-D inclusion criteria of the trials are depicted as well as
the mean HAM-D scores of all the patients at base line.
In the third and fourth trials (De Jonghe et al., 2004; Dekker et al., 2008;
Van, Dekker, et al., 2009), patients with severe depression (HAM-D score
26 or more points) were excluded because it was considered unethical
to offer severely depressed patients only psychotherapy and to withhold
medication.
Exclusion. The exclusion criteria included the presence of any of the
following conditions: a psychoorganic disorder, drug abuse, a psychotic
disorder and/or a dissociative disorder, not being reliable enough to par-
ticipate in a clinical trial (e.g., doctor shopping), serious communication
problem (e.g., language barrier), physical restrictions (e.g., the patient
will soon leave the country), being “too ill” and/or “too suicidal” (e.g.,
hospitalization is unavoidable), pregnancy, or a wish to become preg-
nant. Patients with personality pathology or disorders were not excluded.
Exclusion criteria associated with medication included the following: a
contraindication for one of the antidepressants prescribed by the pharma-
cotherapy protocol, a history of adequate treatment with antidepressants
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Table 3
Participants’ Flow of the Original Five Trials
Trial 1 Trial 2 Trial 3 Trial 4 Trial 5
Assessed for eligibility 525 824 463 612 570
Excluded 358 616 360 471 229
Not meeting inclusion
criteria
113 158 80 132 133
Meeting inclusion
criteria
213 433 251 276 437
Refused 32 25 29 63 73
Randomized 167 208 103 141 341
during the present depressive episode, and use of psychotropic medica-
tion not prescribed by the pharmacotherapy protocol. The inclusion and
exclusion criteria are the usual ones in clinical pharmacotherapy.
Flow of Participants
In the paragraphs, tables, and figures that follow, we will discuss the main
results of the trials. In the second part of this article, we will describe the
secondary analyses of the trials, and we will also present therapy results
of native and nonnative patients in the SPSP arm of the fifth trial. Table 3
shows the participants’ flow of the five trials.
Randomization
All patients in the trials were allocated (through a random allocation
procedure) to one of the treatment conditions. Participants of the fourth
trial of Dekker et al. (2008) who refused to participate in the randomiza-
tion procedure were offered the possibility of receiving treatment (psy-
chotherapy or pharmacotherapy) by preference. The results of this by
preference group (mostly psychotherapy patients) were described by
Van, Dekker, et al. (2009).
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EVIDENCE FOR PSYCHODYNAMIC THERAPY 137
Short Psychodynamic Supportive Psychotherapy
SPSP (see also Driessen et al., 2007) was developed as a treatment for
depressed outpatients in the early 1990s by De Jonghe et al. (2013).
SPSP is rooted in six psychoanalytical theories (described elsewhere;
see De Jonghe et al., 2013). Together these theories posit six innate,
basic, social needs: sexuality, aggression, the need to engage in rela-
tionships, and the need to be protected, loved, and esteemed. If these
needs are inadequately met in early infancy, they persist in adulthood as
ongoing malignant aspects of the internal relationships, acting as moulds
on new external and internal relationships. SPSP considers the gratifica-
tion of these needs particularly relevant in the treatment of depressed
patients. The therapeutic action of SPSP consists in experiencing “rela-
tional dissonance,” or friction between two contradictory relationships,
in the therapeutic situation. One is determined by molds resulting from
past relationships, the other by the present relationship with the ther-
apist, in which the patient will experience adequate gratification of his
unmet early infantile needs. The proper gratification of unmet develop-
mental needs forms the psychoanalytic definition of “support,” which
is considered an important curative factor in SPSP (De Jonghe et al.,
2013).
In general, psychoanalytically oriented psychotherapies can be placed
on a supportive-exploratory continuum. SPSP can be regarded as situ-
ated within the supportive half of this continuum. PTs located on the
exploratory end emphasize the interpretation of transference. SPSP rec-
ognizes the existence of transference but does not interpret it. Specific
to SPSP is the distinction of different levels of discourse within the dis-
cussion of the problem area. Levels 1, 2, and 3 successively focus on the
patient’s physical and psychological symptoms and complaints, the influ-
ence of life circumstances on the depressive symptoms, and the influence
of external interpersonal relationships on the depressive symptoms. At
the fourth and fifth levels, the focus shifts to one or more relational pat-
terns in the patients’ life and the patients’ attitude in life, respectively.
The sixth level concerns the past relationships that persist in the patients’
current life, and the seventh level concerns the intrapersonal relationship
the patient maintains with him- or herself, as a consequence of iden-
tification with these past relationships. At the eighth and ninth levels
the focus shifts to how the problems discussed at levels 4–7 manifest
themselves in the relationship with the therapist. The levels of discourse
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138 JACK J. M. DEKKER, Ph.D. ET AL.
can vary considerably during the course of treatment (De Jonghe et al.,
2013).
As mentioned previously, support is regarded as the most important
curative factor in SPSP and considers support that promotes progres-
sion and maturing behavior as adequate, while regarding support that
promotes regression as inadequate. The therapist explicitly shows a sup-
portive attitude: being empathic, accepting, committed, active, flexible,
clear, definite, patient, and persistent. In addition, the therapist systemat-
ically employs supportive techniques such as reducing guilt, shame, and
isolation, clarifying, confronting, rationalizing, enhancing self-esteem, ad-
vising, and modeling. SPSP, as described by De Jonghe et al. (2013),
constitutes the treatment protocol in the present study. According to this
protocol, SPSP consists of three treatment phases. In the starting phase,
the depressive complaints and their interpersonal context are as follows:
psychoeducation about depressive disorders is given; treatment aims are
established; and a treatment proposal is made. The second phase is de-
voted to working on the treatment aims, which usually relate to one of
four interpersonal problem areas: mourning, strife, role transformation,
or isolation. The problem area is discussed according to the different
discourse levels. If possible, a connection is made between the problems
in this area and the internal relationships (level 3 and thereafter). Pa-
tients are encouraged to experience their emotions and to reflect upon
them. In addition, patients are encouraged to change their behavior and
cognitions, the consequences of which are discussed. The final phase
deals with the treatment termination, including any mourning that arises
around ending. The treatment aims are evaluated, as well as the patient’s
perception of the treatment process. In addition, the patient’s progno-
sis is considered and attention is given to affirmation of the patient’s
independence and handling of possible problems in the future.
In all trials, patients received 16 sessions of manualized SPSP (De
Jonghe et al., 2013), a form of time-limited dynamic psychotherapy dur-
ing a period of six months (De Jonghe et al., 2013). SPSP focuses on
the affective, behavioral, and cognitive aspects of relationships that can
be discussed from both an interpersonal or intrapersonal perspective.
Depending on the focus of therapy and the capacities of the patient,
the therapists’ interventions are primarily directed at providing support
(e.g., encouraging adaptive coping, reducing feelings of guilt, providing
explanations) or enhancing insight by confrontation or interpretation.
Manifestations of transference are recognized by the therapist and, if it is
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EVIDENCE FOR PSYCHODYNAMIC THERAPY 139
likely to be beneficial, discussed to facilitate the therapeutic process. This
means that the technique used in SPSP can vary across the supportive–
expressive continuum according to individual patient characteristics and
psychological capacities (Gabbard, 2005). The therapists were trained
psychiatrists or psychotherapists. Based on audiotaped material of ses-
sions, the therapists were supervised on a weekly basis.
Pharmacotherapy
Pharmacotherapy was provided in accordance with an antidepressant
medication protocol, which allowed for changes in medication in re-
sponse to inefficacy or intolerance. In the first two trials, fluoxetine was
given as first antidepressant. In the third and fourth trials, patients started
with venlafaxine (for medication protocol, see De Jonghe et al., 2001,
2004; Dekker et al., 2005, 2008).
Medication was provided by a psychiatrist or by an advanced, su-
pervised resident in psychiatry who also conducted psychotherapy, but
never to the same patient. The 15-minute medication consultations took
place once every two weeks during the first two or three months of treat-
ment, and once a month thereafter. In all the trials with a combination
arm, different therapists provided the psychotherapy and pharmacother-
apy.
Therapists
Approximately half of the SPSP therapists were experienced psychiatrists
or psychotherapists, and half of them were residents in psychology and
psychiatry. Therapists were trained in a 16-hour course, and in order to
qualify for being a treatment provider in the study, they needed: (1) to
complete one or more supervised therapies; (2) to be found competent in
practicing SPSP by one of the two supervisors; and (3) if still in training,
they had to participate in a weekly 90-minute group supervision with
tape-recorded sessions ensuring adherence to the psychotherapy manual.
The other therapists met twice a week for peer supervision, this meeting
was chaired by one of the supervisors who also reviewed audiotaped
material to maintain protocol adherence.
Outcome Measures
The principal outcome measure was the difference between the assess-
ments at baseline and those at week 24. The primary instrument was
the 17-item Hamilton Depression Rating Scale (HAM-D; Hamilton, 1967).
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140 JACK J. M. DEKKER, Ph.D. ET AL.
HAM-D data are provided by independent observers (fellows). They
gathered their data using a semi-structured interview (De Jonghe, 1994;
Kupka, De Jonghe, Koeter, & Vermeulen, 1996). In the review of Bagby,
Ryder, Schuller, and Marshall (2004), the interrater reliability (Pearson’s
r) ranged between 0.82 and 0.98. During the study, they discussed their
audiotaped assessments monthly with an expert from our research group.
Obviously, the patients and the treating physicians in the trials were not
blind. The research fellows, however, were given as little information
as possible about the treatment condition and were instructed to restrict
themselves to the discussion of the HAM-D items only. Efficacy is ex-
pressed in success rates. Success is defined as HAM-D remission on the
HAM-D scale, i.e., score ≤ 7.
A second instrument was the Clinical Global Impression of severity
(CGI-severity; Guy, 1976). CGI data were provided by the attending clin-
icians. A third instrument is a self-rating scale: the depression subscale
of the Ninety Symptom Checklist (SCL-depression; Arrindell & Ettema,
1986). CGI of severity success is defined as a final score of 1 (meaning
a normal mood) or 2 (meaning a borderline case between normal mood
and mildly depressive mood). SCL-depression success is defined at the
end of therapy as an improvement of the magnitude of at least 1 stan-
dard deviation (in comparison with the baseline score). In short, efficacy
assessments are based on data drawn from three sources: independent
observers, the treating clinicians, and the patients. The assessments were
done at weeks 4, 8, 12, 16, and 24.
Statistics
In the main articles the methods of analysis were conducted on three
samples of patients. The first sample was an Intention-To-Treat (ITT)
sample and consisted of all the patients who entered the studies for
randomization. The second sample was the Per Protocol (PP) sample:
patients who started with the treatment to which they were allotted.
The third Observed Cases sample consisted of patients who started with
therapy and for whom the data were gathered at the relevant assessment
points.
Results
Patients. In all the trials, the patient groups were more or less equal to
each other; two-thirds were women; about 60% were between 20 and 40
(average age 38); 70–80% had received secondary to higher education;
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60% cohabited with at least one other person and 40% lived alone; about
20–30% were married; 35% had a job; 30% had been on sick leave for
some time; 40–50% had experienced one of more previous depressive
episodes; 20–40% had taken medication in the past months; for 30–50%,
the duration of the present episode was longer than one year; and the
mean HAM-D score of approximately 19 and the mean SCL-90 score of
about 49 were far above the national average (De Jonghe et al., 2001,
2004; Dekker et al. 2005, 2008, 2013).
There is a slight trend of patients having more severe problems; more
patients with more depressive episodes; more medication use at intake;
a longer duration of the present episode. This trend is related to the
fact that the outpatient clinics of later trials were more often located in
lower-class and deprived areas.
Main results of the trials. In the first trial, we (De Jonghe et al., 2001,
p. 228) concluded that combined treatment (SPSP plus pharmacother-
apy) was significantly more beneficial than pharmacotherapy alone. Also,
there were significantly fewer dropouts in the combined therapy and,
ultimately, there were significantly more patients recovered in the com-
bined therapy (see the percentages of recovered patients in the secondary
analyses of this article). So, combined therapy seemed preferable to phar-
macotherapy in the treatment of depressed outpatients.
In the second trial we (Dekker et al., 2005, p. 55) found that 8 or 16
psychotherapy sessions in addition to pharmacotherapy over a period of
six months appeared to be equally effective in dealing with symptoms.
That was true for both moderately and severely depressed patients.
In the third trial, our conclusion (De Jonghe et al., 2004, p. 44) was that
psychotherapy alone (SPSP) was more beneficial than combined therapy
(SPSP plus pharmacotherapy). The six-month feasibility of psychother-
apy was fair, that of combined therapy was good: 25% of the patients in
the psychotherapy condition broke off their therapy; 16% did so in the
combined therapy group. Nonetheless, both therapies were efficacious
in reducing the symptoms of depression. The advantages of combin-
ing antidepressants with SPSP appeared equivocal. Neither the attending
clinicians nor the independent observers were able to ascertain this, but
patients’ experiences were clearly in favor of combined therapy.
In the fourth trial, we (Dekker et al., 2008, p. 4) have determined
which sequence is preferable for the acute treatment of depression: start-
ing with SPSP or with pharmacotherapy. This trial started with a random-
ized clinical trial of eight weeks, making a direct comparison possible
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between antidepressants and SPSP. To our knowledge, a psychodynamic
psychotherapy was never before compared directly to treatment with an-
tidepressant medication. In the first article of this trial, we reported that
the benefit of the psychotherapy SPSP was greater than pharmacother-
apy. Of the 204 patients suitable for the study, 141 were randomized for
SPSP or antidepressants. The remaining 63 patients refused randomiza-
tion because they did not want to get antidepressants.
In a by-preference model (Van, Dekker, et al., 2009), these patients
were offered a choice between SPSP or antidepressants. Almost all the
patients preferred SPSP and not antidepressants. The feasibility for both
treatment conditions (SPSP or antidepressants) throughout the first eight
weeks in this study was almost similar. The study attrition rates (about
28%), in comparison to other studies, reported dropout rates of 33–48%
within the first six to eight weeks (Anderson, Nutt, & Deakin, 2000;
Linden, Gothe, Dittmann, & Schaaf, 2000). The efficacy of SPSP and
antidepressants in the first eight weeks was not equivalent. We found
slightly better results for antidepressants by week four. This benefit had
almost disappeared by week eight.
The second article of this trial (Dekker et al., 2013) covered the entire
course of treatment of six months and focused on the differential efficacy
(at 24 weeks) of the treatment strategies. At eight weeks, all patients with
less than a 30% decrease in symptoms were offered combined therapy
for an additional period of 16 weeks. Nonresponsive patients receiv-
ing antidepressants were therefore offered complementary PT, whereas
nonresponsive patients receiving PT were offered complementary an-
tidepressants. Stepped-care strategies, like the one in this study, seemed
clinically logical, but in our study about 40% of the patients declined the
offer of additional therapy, despite the limited effect of monotreatment.
The acceptance rate for SPSP or antidepressants after nonresponse was
similar in both conditions. Given the widespread support for and imple-
mentation of stepped care and sequential treatment strategies, this was
an unexpected finding. Concerning efficacy of the two sequential strate-
gies (antidepressants after unresponsive SPSP or SPSP after unresponsive
antidepressants), we found that patients receiving psychotherapy from
the outset were better off by week 24 (end of treatment), compared to
those receiving pharmacotherapy. Our final conclusion was that SPSP has
a somewhat slower start than pharmacotherapy alone in the first eight
weeks of treatment, but that SPSP prevailed on most assessments in the
end.
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In the fifth trial (Driessen et al., 2013), noninferiority was shown of SPSP
relative to CBT for posttreatment observer- and patient-rated depression
scores. Based on observed data, 24.3% of the patients in the CBT condi-
tion and 21.3% in the SPSP condition met the remission criterion at the
posttreatment assessment. Our conclusion was that the results contribute
to the evidence base of psychodynamic therapy for depression.
Reduction of depressive symptoms during treatment. In the first four
trials, the efficacy of pharmacotherapy alone is examined in two trials
(trials 1 and 4). The efficacy of SPSP (with 16 sessions) alone was exam-
ined in two trials (trials 3 and 4) and the efficacy of SPSP (16 sessions) in
combination with antidepressants from the onset was examined in three
trials (trial 1, 2, and 3). We will now give an impression of the reduction
of symptoms during treatment of pharmacotherapy alone, of SPSP alone,
and of SPSP in combination with antidepressants.
The mean HAM-D scores of pharmacotherapy during treatment in two
trials diminished during the first 12 weeks, but became higher again
towards the end of the therapy. It seems that at that point medication
reached the lowest point of symptoms reduction.
In the Per Protocol Sample of trial 1, the success of pharmacotherapy,
according to the independent research fellow (HAM-D <8), was about
23%, the success according to the doctor (CGI-Severity below 3) was
about 48%, and the success according to the patient was about 55%. In
trial 4, these success percentages were 9%, 32%, and 53%. In the SPSP
alone condition, we did not see such a bend of scores. At the end of
therapy, the reduction of depressive symptoms continued.
In the Per Protocol Sample of trial 3, the success of SPSP alone, ac-
cording to the independent research fellow, was about 32%, the success
according to the therapist was about 67%, and the success according to
the patient 60%. In trial 4, these success percentages were 27%, 49%, and
52%.
Looking at the combined treatment, we did not see a bend up towards
the end either. The HAM-D scores at the end of therapy were also lower
than the ones in pharmacotherapy and SPSP alone.
In the Per Protocol Sample of trial 1, the success of combined therapy,
according to the independent research fellow, was about 43%, the success
according to the doctor was about 63%, and the success according to the
patient was about 75%. In trial 2, these success percentages were 29%,
47%, and 60%, respectively. In trial 3, the success percentages were, 43%,
79%, and 77%, respectively.
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Figure 1. Mean outcome of all four trials.
In Figure 1 the mean HAM-D scores during treatment of pharmacother-
apy alone (trials 1 and 4), of SPSP alone (trials 3 and 4) and of the com-
bination of SPSP and pharmacotherapy (trials 1, 2 and 3) are depicted.
As you can see, at the end of treatment, SPSP alone is closer to combined
therapy than to pharmacotherapy alone.
Figure 2 shows the mean scores on the Hamilton Depression Rating
Scale of SPSP and CBT of study 5 (Driessen et al., 2013). The depression
scores of both conditions (SPSP; dotted line, and CBT; black line) improve
during treatment.
Observed response rates were 38.7% for CBT and 36.9% for SPSP.
The percentage of patients who met the remission criterion at posttreat-
ment assessment was 24.3% of the patients in the CBT condition, and
21.3% of the patients in the SPSP condition (OR = .82; 0.45–1.50). No
statistically significant treatment differences were found on any of the
three outcome measures, both posttreatment and at the follow up. This
study was recently published in American Journal of Psychiatry. Dr. M.
E. Thase (2013) dedicated an editorial to the study and concluded: “On
the basis of these findings, there is no reason to believe that psycho-
dynamic psychotherapy is a less effective treatment of major depression
than CBT. This large study expands the literature on controlled studies of
psychodynamic psychotherapy, which heretofore was relatively meager”
(p. 954).
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Secondary Analyses
Influence of Presence of Personality Disorders on Outcome
In 2005, Kool wrote a thesis on the influence of personality disorders
on treatment outcome (Kool, 2005). The primary research aim of the
thesis was to determine and study the characteristics of the subgroup
of depressed patients with comorbid personality disorders, compared to
the group without personality disorders. The data used were drawn from
the same study that De Jonghe et al. (2001) used. The researcher drew
the following conclusion: depressed patients with a comorbid personal-
ity disorder turned out to have more severe scores of depression. The
following conclusion was surprising: For depressed patients without a
personality disorder, there was no justification for adding psychother-
apy to pharmacotherapy as treatment results did not differ significantly
between the conditions. However, for depressed patients with person-
ality disorders, combined therapy was significantly more effective than
pharmacotherapy. These superior results are related to the characteris-
tics of SPSP. The short-term, anti-regressive, and structured nature of
this therapy and its focus on relationships, impairments in social func-
tioning, and quality of life seem essential ingredients for improvement in
the group with comorbidity. Reviewing the follow-up data, the researcher
Mean Hamilton Depression Rating Scale (HAM-D) score during treatment 
0
5
HAM-D  10
15
20
25
1 3 5 7 9 11 13 15 17 19 21
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Figure 2. Mean outcome of trial 5.
D
ow
nl
oa
de
d 
by
 [2
17
.12
2.2
52
.24
] a
t 0
2:2
4 2
0 J
un
e 2
01
4 
146 JACK J. M. DEKKER, Ph.D. ET AL.
concluded that there was a significant reduction in personality pathology.
In the combined group, this was found not only in patients who had re-
covered from depression, but also in patients who had not recovered.
In the pharmacotherapy condition, the significant decrease in personality
pathology was restricted to patients who had recovered from depression.
The last conclusion was that no significant differences in remission rates
were found between the groups with and without personality disorders.
Predictors of Outcome
In Van’s thesis, predictive factors for outcome of SPSP were explored.
In a review, Van, Schoevers, and Dekker (2008) concluded that easily
identifiable factors such as age, gender, marital status, and duration of
depression may be predictive for outcome. They also found that predic-
tors were different across treatment options, which makes them poten-
tially clinical relevant for selecting the optimal approach in an individual
patient.
With the data of our trials, Van, Schoevers, Peen, van Aalst, and Dekker
(2008) first investigated the role of easily identifiable patient characteris-
tics such as gender, age, severity, and duration of depression. The patient
sample consisted of 97 patients treated with SPSP only and 171 patients
with the combination of SPSP and antidepressants (the third trial). In
SPSP alone, an unfavorable outcome appeared to be related to older age
and longer duration of the depression and to severity of comorbid anx-
iety and somatic symptoms. In contrast, these results were not found in
combined therapy, suggesting these patients needed to be treated with
antidepressants as well. Comparing SPSP alone with combined therapy
revealed that the later was more favorable for patients with anxiety. It
was also found that although in general patients with an early nonre-
sponse are at risk for ultimate treatment failure, a considerable number
of early nonresponsive patients required more time before favorable ef-
fects became noticeable. This suggests that it is worthwhile to continue
treatment despite absence of initial improvement (Van, Schoevers, Kool,
et al., 2008).
With respect to psychodynamic factors, adaptive level of object re-
lational functioning was only very modestly related to outcome (Van,
Hendriksen, et al., 2009). Defense styles appeared to be more relevant
(Van, Schoevers, Peen, Abraham, & Dekker, 2009). Especially patients
with a so-called “symbiotic defense” style characterized by giving up and
apathetic withdrawal were at risk for both drop-out and poor outcomes.
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What is remarkable and in line with theoretical considerations is that
patients using more neurotic styles such as affect denial and repression
showed a more favorable outcome.
Influence of Patients’ Ethnic Background on Outcome
In the first two trials, not many patients of different ethnic minorities
participated in the trials. In the third trial, 14 patients of ethnic minorities
(about 7%) participated in the study. In the fourth trial, 22 patients of eth-
nic minorities (about 16%) participated. In the fifth trial, the participation
of ethnic minorities was much higher. In a total sample of 342 patients,
about 44% patients (N = 150) were of ethnic minorities. About 30% of
these patients came from Surinam, 30% from Morocco, 15% from Turkey,
and 25% from other countries. There were no significant differences be-
tween the native and nonnative group of patients concerning gender,
working situation, duration of depression, recurrence, or working situ-
ation. However, nonnatives were significantly younger, lived together
more frequently with at least one other person, and were less highly
educated than the native patients. Nonnative patients were slightly more
depressed at the beginning of treatment, and they remained so to the
end, but their amount of improvement in the SPSP condition was similar
and not significantly different than for the native patients.
Discussion
About 25 years ago, we began to look for evidence of effectiveness of the
psychodynamic treatment of depression. Evaluating all the research re-
sults of the five trials we can safely say that PT (short term and supportive
in the form of SPSP) has proven to be effective. The depression slopes in
the figures speak for themselves. Adding SPSP to antidepressants yields
better results than antidepressants by itself. Adding medication to SPSP
may have a significant added value, but it is not as big as in the first
comparison. Effectiveness of antidepressants appears to set in quicker
than SPSP on its own, but in the end SPSP (with or without the addition
of antidepressants after eight weeks) seems better than the evidence-
based pharmacotherapy (with or without the addition of SPSP after eight
weeks). And last but not least, the results of the trials confirm no dif-
ference in efficacy between CBT and SPSP. So, it is justified to qualify
SPSP as an empirically supported therapy form of PT for depression. In
the earlier mentioned editorial, Dr. Thase (2013) reached the same con-
clusion: “The study by Driessen et al. is noteworthy because it provides
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some of the strongest evidence to date that short-term psychodynamic
psychotherapy is an effective treatment for major depression” (p. 953).
Several studies in the last few decades (Leichsenring, 2001; Driessen
et al., 2010) have demonstrated evidence for the effectiveness of PT for
depression. In the latest Dutch guidelines for the treatment of depres-
sion, our studies of SPSP, together with these meta-analyses, contributed
significantly to qualify PT as an evidence-based treatment. In the former
guideline (Kwaliteitsinstituut voor de Gezondheidszorg, 1994), that was
not the case and only CBT and interpersonal therapy were considered
the standard treatments. We were very pleased that the tide had turned
now. However, in England, in the most recent guideline (NICE, 2009),
PT as evidence based treatment for depression was still considered con-
troversial.
In 2010, psychodynamic-oriented researchers and therapists therefore
developed a protocolized form of PT named dynamic interpersonal ther-
apy (Lemma, Target, & Fonagy, 2011), which they are now testing in a
randomized trial in comparison to CBT.
Retrospect
In the 1990s, the developer of SPSP (De Jonghe in the Netherlands)
added two elements to PT that were sometimes considered controversial
in the psychoanalytic community, but previously had been determined
necessary in treating patients, i.e., the therapeutic strength of adequate
support. This is in line with Wallerstein’s (1989) study, indicating that
psychoanalysis is both more supportively conducted by therapists and
supportively experienced by patients than initially thought. In addition,
theoretical considerations by Misch (2000) on the aims and application
of supportive therapy were used.
The choice for the emphasis on adequate support was closely related
to the serious and often chronic depressive conditions of the patients re-
ferred to our departments. These patients have to deal with heavy suffer-
ing and significant disturbance of psychosocial functions. The depressive
symptoms that could be seen in affects, thoughts, and behavior are often
based on a relational etiology. Interpretation of this meaning is easily
experienced as a confirmation of the already excessive self-criticism and
judgment and does not lead to increased insight. Adequate support by
enhancing ego functions is more justified at that moment. It was and is
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indeed important that the support is adequate; in other words, that it is
actually directed at growth and development.
Looking back at our earlier randomized research into SPSP has been an
inspiring enterprise for our research group. In the 20 years that we have
done the five trials, we have treated a broad group of approximately 900
patients with depression.
In retrospect, we believe it would have been better to compare SPSP
with a waiting list condition or a placebo condition in an earlier phase as
this would have contributed sooner to an evidence based qualification
of SPSP. The reason we did not do this had to do with the spirit of the
times 20 years ago. At that time, it was simply not permitted to deny
depressive patients immediate treatment. However, other approaches,
such as CBT and internet therapy, have done so. This has contributed to
quicker acceptance as an empirically supported therapy.
Another reflection is that we did not expand the most important find-
ings of the second trial by pursuing a line of research into the long-term
effectiveness of short-term therapies.. The finding of this trial was that
eight sessions of SPSP did as well as 16 sessions of SPSP in the combined
version.
However, we felt therapists were reluctant to perform the eight ses-
sions as a monotreatment. They felt that eight was too few; therefore we
did not continue that line of research. Looking back, we now feel that
was a pity. Presently, health insurance companies are applying strong
pressure to keep mental-health treatment as short and as cheap as possi-
ble. Because of financial pressure, mental health care organizations need
to react to that. For instance, it has become a trend to reduce evidence-
based treatments from 16 to 12 sessions or duration from 45 to 30 minutes.
All this with the aim of offering a cheap package price for treatment of
depression. From a clinical and scientific point of view, however, this
can be considered as a risk of undertreatment that needs to be opposed
until research confirms that these types of reductions are justified.
Today
The last trial in which SPSP and CBT were compared will be in fact the
proof of the pudding because it is a direct comparison of SPSP with the
most established empirically supported treatment for depression. How
did we manage to work together with therapists form two opposite ori-
entations? Each year, all CBT and SPSP therapists were invited to a joint
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meeting to discuss the progress of the research. During these meetings,
there was a constructive and competitive atmosphere where our treat-
ment successes were described and the laborious struggles to record
progress with difficult patients were critically discussed.
The findings of our trials show that after an additional theoretical
course in psychodynamics, and under close supervision, SPSP can be
applied by psychologists and residents with relatively little other expe-
riences in psychoanalysis or psychodynamic psychotherapy. Related to
this, the Dutch Society for Psycho-Analytical Psychotherapy (NVVP) has
opened a section where psychologists, psychotherapists, and psychia-
trists could be officially registered as SPSP therapists.
This meant that not only therapists but also patients could be offered
a choice for their preferred treatment approach—in short, SPSP as “talk-
ing about the emotional and relational background of the depression” or
CBT as “working on a change in cognition and behavior.” Both interven-
tions are probably equally effective to reduce depressive symptoms, but
possibly not equally effective in every individual patient.
The Future
One of the objectives for SPSP in the near future is to add more specific
mechanisms of change, emphasizing such things as behavioral activation
during the first few weeks of treatment. In our fourth trial, it turned out
that a reduction of symptoms was achieved less quickly during the first
four weeks of treatment in SPSP than pharmacotherapy. Our explanation
is that pharmacotherapy probably leads to more rapid symptom reduc-
tion, e.g., a better sleeping pattern, resulting in feelings of hope. A further
development of the SPSP protocol may be profitable.
Stepped care is essential. Although the effectiveness of PT has been
shown, there is still a large number of depressive patients who do not
reach complete remission, varying from 25-45%. CBT and interpersonal
therapy have very similar remission rates; possibly this suggests that all
forms of short-term psychotherapy achieve a ceiling effect at this level.
Essentially, it is not known what to do to get higher remission rates
because there are no high quality follow-up trials in psychotherapy. In
addition, several studies have showed that incomplete remission is the
most important risk factor for future relapse. So, there is a strong need
to improve treatment results.
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In our view, there are various options. Outcomes of depression treat-
ment may be related to therapy doses. It is suggested that remission
rates depend on intensity and duration of therapy (Keller, 2001), but we
need to study that more rigorously in controlled designs. It is therefore
relevant to know whether increasing treatment dose (in frequency and
duration) can improve remission rates. A different approach is to offer
booster sessions after acute treatment is ended. It is well known that
these booster sessions reduce the possibility of relapse, although the ef-
fect is small, about 20% lower over a period of two years (e.g., Bockting
et al., 2005). So far this has only been studied for booster sessions after
CBT or interpersonal therapy and not for PT.
Matched care where necessary. Sufficient studies show the effective-
ness of long-term PT. Specifically, we are talking about PT for (almost
always) patients with a combination of several disorders, on Axis I as
well as on Axis II, which have a chronic course and to whom previously
treatments were not successful (Leichsenring & Rabung, 2011). Maybe
we should consider more long-term treatment options for these types of
patients. The same may be true for patients with high levels of comor-
bidity such as personality disorders, anxiety disorders, and posttraumatic
stress disorders.
International collaboration. More international collaboration between
schools of different treatment approaches is needed. Short-term and pro-
tocolized supportive psychodynamic therapies such as SPSP, dynamic in-
terpersonal therapy, and supportive expressive therapy (Luborsky, 1984;
Barber & Crits-Christoph, 1995) will likely show more similarities than
differences. Most ideal for the near future would be for an international
study group to transform the best elements of each short-term psychody-
namic therapy into an international collective short-term PT (protocolized
and documented), not only for depression, but also for anxiety and per-
sonality disorders. International collaboration is highly desirable in the
case of clinical relevant efficacy and efficiency. Such an initiative has re-
cently been established for long-term treatment of personality disorders.
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